Adam Bonislawski
Adam covers proteomics and the clinical lab market for GenomeWeb.

Articles Authored by Adam Bonislawski
The agency has suggested approaches like third-party review would help manage the expected influx of submissions, but labs and vendors remain concerned.

Proteomics International Expects Licensing Deal, Medicare Coverage to Drive PromarkerD Sales in 2024
Premium
The company is making its first major commercial push for its diabetic kidney disease test via a US licensing deal it inked this spring with Sonic Healthcare.
The agency has rebuffed calls to extend its public comment period, with the upcoming election and the next user fee cycle likely influencing its timeline.

Roughly a year after its launch, the company's Multiple Sclerosis Disease Activity (MSDA) test is being used by several dozen clinics around the country.
Quanterix Plans to Wrap up Restructuring by End of Year; Q3 Revenues Grow 18 Percent
The company posted Q3 2023 revenues of $31.3 million, up from $26.6 million in Q3 2022 and beating the consensus Wall Street estimate of $27.6 million.
Following a recent leadership change, glycoproteomics firm InterVenn Biosciences is reevaluating its commercial strategy and direction.
OIG Report Finds Lack of Experience, Lab Resources Led to CDC COVID-19 Test Failure
The agency's initial failure to develop a COVID-19 test stemmed from factors ranging from inexperienced staff to a lack of quality safeguards and physical resources, OIG said.

Labcorp Projects $80M Hit to 2024 Revenues Without PAMA Fix, Suggests Openness to FDA LDT Regulation
Premium
The company also reported Q3 revenues of $3.06 billion, up from $2.87 billion in Q3 2022 and above the consensus Wall Street estimate of $2.99 billion.
With the calendar winding down and the House without a speaker, the PAMA reform bill could stall again this year, though another temporary fix may be in the offing.
The firm, which reported an 8 percent drop in Q3 total revenues but a 5 percent rise in base business revenues, is closely watching federal action on these two lab industry priorities.
